Cargando…

m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer

Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains un...

Descripción completa

Detalles Bibliográficos
Autores principales: Ye, Xin, Wang, Ruyi, Yu, Xiaoqian, Wang, Zili, Hu, Haifeng, Zhang, Hanchao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596993/
https://www.ncbi.nlm.nih.gov/pubmed/36313300
http://dx.doi.org/10.3389/fphar.2022.1030766
_version_ 1784815994075611136
author Ye, Xin
Wang, Ruyi
Yu, Xiaoqian
Wang, Zili
Hu, Haifeng
Zhang, Hanchao
author_facet Ye, Xin
Wang, Ruyi
Yu, Xiaoqian
Wang, Zili
Hu, Haifeng
Zhang, Hanchao
author_sort Ye, Xin
collection PubMed
description Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains unclear. We explored the expression patterns of the MRGs in the genome and transcriptional fields of 796 prostate cancer (PCa) samples using two separate data sets. We identified a relationship between patient clinicopathological characteristics, prognosis, TME cell infiltrating qualities, and different MRG changes, as well as the identification of two distinct molecular groupings. Then, we formed an MRGs model to predict overall survival (OS), and we tested the accuracy of the model in patients with PCa. In addition, we developed a very accurate nomogram to improve the MRG model’s clinical applicability. The low-risk group had fewer tumor mutational burden (TMB), greater tumor immune dysfunction and exclusion (TIDE) ratings, fewer mutant genes, and better OS prospects. We discuss how MGRs may affect the prognosis, clinically important traits, TME, and immunotherapy responsiveness in PCa. In order to get a better understanding of MRGs in PCa, we could further explore the prognosis and create more effective immunotherapy regimens to open new avenues.
format Online
Article
Text
id pubmed-9596993
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95969932022-10-27 m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer Ye, Xin Wang, Ruyi Yu, Xiaoqian Wang, Zili Hu, Haifeng Zhang, Hanchao Front Pharmacol Pharmacology Methylation has a close relationship with immune reactions, metastasis, and cancer cell growth. Additionally, RNA methylation-related proteins have emerged as potential cancer therapeutic targets. The connection between the tumor microenvironment (TME) and methylation-related genes (MRGs) remains unclear. We explored the expression patterns of the MRGs in the genome and transcriptional fields of 796 prostate cancer (PCa) samples using two separate data sets. We identified a relationship between patient clinicopathological characteristics, prognosis, TME cell infiltrating qualities, and different MRG changes, as well as the identification of two distinct molecular groupings. Then, we formed an MRGs model to predict overall survival (OS), and we tested the accuracy of the model in patients with PCa. In addition, we developed a very accurate nomogram to improve the MRG model’s clinical applicability. The low-risk group had fewer tumor mutational burden (TMB), greater tumor immune dysfunction and exclusion (TIDE) ratings, fewer mutant genes, and better OS prospects. We discuss how MGRs may affect the prognosis, clinically important traits, TME, and immunotherapy responsiveness in PCa. In order to get a better understanding of MRGs in PCa, we could further explore the prognosis and create more effective immunotherapy regimens to open new avenues. Frontiers Media S.A. 2022-10-12 /pmc/articles/PMC9596993/ /pubmed/36313300 http://dx.doi.org/10.3389/fphar.2022.1030766 Text en Copyright © 2022 Ye, Wang, Yu, Wang, Hu and Zhang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ye, Xin
Wang, Ruyi
Yu, Xiaoqian
Wang, Zili
Hu, Haifeng
Zhang, Hanchao
m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title_full m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title_fullStr m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title_full_unstemmed m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title_short m(6)A/ m(1)A /m(5)C/m(7)G-related methylation modification patterns and immune characterization in prostate cancer
title_sort m(6)a/ m(1)a /m(5)c/m(7)g-related methylation modification patterns and immune characterization in prostate cancer
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9596993/
https://www.ncbi.nlm.nih.gov/pubmed/36313300
http://dx.doi.org/10.3389/fphar.2022.1030766
work_keys_str_mv AT yexin m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer
AT wangruyi m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer
AT yuxiaoqian m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer
AT wangzili m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer
AT huhaifeng m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer
AT zhanghanchao m6am1am5cm7grelatedmethylationmodificationpatternsandimmunecharacterizationinprostatecancer